Eleven Biotherapeutics Inc. (Nasdaq: EBIO) reported disappointing results from a Phase 3 clinical trial of its severe allergic conjunctivitis treatment isunakinra prompting a downgrade. The stock price plummeted $1.82 to $0.52.
Eleven Biotherapeutics disappoints
January 19, 2016 at 14:27 PM EST
